Mankind Pharma FY26 Results Show 27% EBITDA Margin
Key highlights
- Mankind Pharma's Q4 FY26 revenue rose 11.8% year on year to Rs 34.4 billion.
- Q4 FY26 EBITDA increased 31.3% to Rs 9.3 billion, lifting the margin 400 basis points to 27.0%.
- FY26 revenue increased 17% to Rs 142.8 billion, while reported net income fell 3.7% to Rs 19.1 billion.
- Q1 FY27 chronic therapies grew 15.8%, taking chronic products to about 40% of domestic sales.
powered by IRIS

Fourth-quarter performance exceeds estimates
Know Mankind Pharma inside out
Results, valuation, peers and who's buying, in one view.
Mankind Pharma closed FY26 with fourth-quarter sales of Rs 34.4 billion, up 11.8% year on year and broadly in line with Motilal Oswal Financial Services' estimate of Rs 34.3 billion. The larger surprise came from profitability. EBITDA rose 31.3% year on year to Rs 9.3 billion, exceeding MOFSL's Rs 8.3 billion estimate. EBITDA margin expanded 400 basis points to 27.0%, compared with the broker's expectation of 24.3%. Adjusted profit after tax increased 80% to Rs 5.8 billion, also ahead of the Rs 4.4 billion estimate. Lower interest costs, higher other income and a lower tax rate supported the adjusted profit figure.
FY26 revenue reaches Rs 143 billion
For FY26, Mankind Pharma reported revenue of about Rs 143 billion, EBITDA of about Rs 36 billion and adjusted PAT of about Rs 20 billion. Separately reported full-year figures showed revenue of Rs 142.8 billion, up 17% from FY25, and net income of Rs 19.1 billion, down 3.7%. The difference between adjusted PAT and reported net income reflects the use of different profit measures in the available disclosures. Full-year earnings per share was Rs 46.35, compared with Rs 49.17 in FY25. The quarterly operating performance nevertheless showed a substantial improvement in margin compared with the prior year period.
Domestic prescription business drives sales
The domestic business contributed 84% of fourth-quarter sales and grew 13.4% year on year to Rs 28.9 billion. Prescription products represented 93% of domestic sales and rose 12.9% to Rs 26.7 billion. Stronger chronic-therapy demand was an important contributor to this performance. The BSV specialty business also supported domestic growth during the quarter. Consumer Health accounted for 7% of domestic sales and grew 19.8% to Rs 2.1 billion, led by Manforce, Prega News, Gasofast and Nimulid.
Base India business shows recovery signs
Kotak Securities upgraded Mankind Pharma to Buy in its September 22, 2026 update, citing improving domestic momentum and market-share gains in brands. The broker said the base India business, excluding Bharat Serums and Vaccines, had begun to normalise after a prolonged restructuring impact. Secondary sales growth excluding BSV improved to 12.7% year on year in Q1 FY27. Growth accelerated to 14.6% during July and August 2026, 120 basis points above the Indian Pharmaceutical Market. According to IQVIA data cited by Kotak, nine of Mankind's top 15 brands excluding BSV gained market share between June 2025 and June 2026.
Export growth moderates in the quarter
Exports made up 16% of fourth-quarter sales and rose 4.2% year on year to Rs 5.6 billion. Although quarterly export growth slowed, FY26 export revenue increased 34.5% to Rs 20.6 billion. The base international business and the BSV portfolio supported full-year growth. In Q1 FY27, exports rose 29% to Rs 6.0 billion, aided by product launches, favourable currency movements and BSV traction. Mankind excluding BSV launched one product in the US during that quarter, taking cumulative launches to 49.
Got a follow-up? Ask IRIS
Q1 FY27 results show a mixed follow-through
MOFSL retained its Buy recommendation following Mankind Pharma's July 31, 2026 results update. Q1 FY27 sales were Rs 40.3 billion, up 12.9% year on year and slightly above the broker's Rs 39.9 billion estimate. EBITDA grew 24.7% to Rs 10.6 billion, while EBITDA margin rose 250 basis points to 26.2%. However, the margin was below MOFSL's 27.7% expectation. Adjusted PAT rose 31.5% to Rs 5.7 billion but missed the broker's Rs 6.5 billion estimate due to lower other income and a higher tax rate.
Chronic therapies strengthen the mix
Chronic therapies grew 15.8% year on year in Q1 FY27, ahead of the 10.9% growth reported in acute therapies. The chronic mix increased by 80 basis points to about 40% of domestic sales. This shift helped gross margin, which rose 225 basis points to 72.8% in Q1, supported by pricing, a more favourable chronic mix and a favourable base. The BSV portfolio grew 21% year on year, including 17% growth in domestic BSV revenue and 25% growth in international BSV revenue. Consumer Health was the weaker segment in Q1, increasing only 3.9% to Rs 2.5 billion.
Broker estimates point to earnings acceleration
MOFSL expects Mankind's earnings to re-accelerate after two relatively stable years and forecasts a 22% earnings CAGR over FY26-28. It reduced its FY27 earnings estimate by 4% because of muted Consumer Health performance. Kotak Securities expects earnings per share to compound at about 23% between FY26 and FY29E. Both broker views depend substantially on the recovery in the domestic prescription business, sustained BSV growth and operating-margin delivery. The reported data show improving domestic secondary sales and brand shares, while Consumer Health remains an area requiring closer monitoring.
Board considers September-quarter results
Mankind Pharma informed exchanges that its board meeting was scheduled for October 26, 2026, to consider unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company was also reported to have declared results on October 26. Investors will assess the September-quarter disclosures for evidence that domestic growth, gross-margin expansion and BSV momentum have continued. The company’s FY26 fourth-quarter performance established a stronger margin base, while the subsequent Q1 update showed that profit conversion can still be affected by other income, tax and Consumer Health trends.


